PS-070 Thromboprophylaxis optimisation in a cohort of neurocritical patients

BackgroundNeurocritical patients have a significant risk of developing further venous thromboembolisms. Therefore, appropriate use of pharmacological and mechanical thromboprophylaxis (TP) is needed to reduce the incidence of these events.PurposeThe aim of this study was to compare the use of TP in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2017-03, Vol.24 (Suppl 1), p.A257-A260
Hauptverfasser: Rivera-Sanchez, L, Lalueza-Broto, P, Juarez-Gimenez, JC, Girona-Brumos, L, Robles-Gonzalez, A, Baguena-Martinez, M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A260
container_issue Suppl 1
container_start_page A257
container_title European journal of hospital pharmacy. Science and practice
container_volume 24
creator Rivera-Sanchez, L
Lalueza-Broto, P
Juarez-Gimenez, JC
Girona-Brumos, L
Robles-Gonzalez, A
Baguena-Martinez, M
description BackgroundNeurocritical patients have a significant risk of developing further venous thromboembolisms. Therefore, appropriate use of pharmacological and mechanical thromboprophylaxis (TP) is needed to reduce the incidence of these events.PurposeThe aim of this study was to compare the use of TP in two cohorts of neurocritical patients, before and after implementation of corrective measures.Material and methodsA retrospective study of the use of TP was performed in two cohorts of neurocritical patients during their stay in the intensive care unit (ICU). The study was undertaken for the period of time from July to September 2013, and from July to September 2016. Demographic and TP related data were collected. Patients with anticoagulant therapy prior to hospital admission were not included.ResultsWe included 30 patients (86.6% men), mean age 45.5 years (16–80) in 2013, and 20 patients (75% men), mean age 48.7 years (17–83) in 2016. Median length of stay in the ICU was 17 days (3–51) in 2013 and 16 days (4–48) in 2016. The main diagnoses at admission in 2013 and 2016 were, respectively, acute spinal cord injury (30% vs 50%), stroke (26.6% vs 0%), head injury (23.3% vs 35%) and subarachnoid haemorrhage (3.3% vs 15%). 2013 2016 Mechanical prophylaxis alone (intermittent pneumatic compression, IPC) Treated patients3.8%15%MST1.71 (same day)MTD12.318.5 Pharmacological prophylaxis alone (LMWH) Treated patients48.1%20%MST5.43.25MTD8.710 Mixed prophylaxis (IPC+LMWH) Treated patients48.1%65%MST13.74.8MTD11.919.8MST, mean days before treatment; MTD, mean days of treatment.ConclusionAfter TP corrective measures were implemented, we observed the following improvements:100% of patients received some method of TP, exceeding the 90% recommended by the Spanish Intensive Society (quality indicator selected), and higher than in 2013 (90%).There was an improvement in TP startup time, both mechanical TP and pharmacological TP, as recommended by different clinical practice guidelines.An increase in the use of mechanical (51.9% vs 80%) and mixed prophylaxis (48% vs 65%) was documented.No conflict of interest
doi_str_mv 10.1136/ejhpharm-2017-000640.576
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2552763002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552763002</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1002-6686d03ee22d98ef2b87bea7f716115716b4c375fdc7cc66f1a914555046f66d3</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMouKz7HwKeu06SZtIeZfELFhVczyFtU5pl29S0BffmxT_qLzHLqkcvM3N4eN_hIYQyWDIm8Mpum74xoU04MJUAAKawlApPyIxDqpI8x_T075Z4ThbD4AqQQmR5KvIZeXx-SUDB18fnpgm-LXwffN_sd-bdDdT3o2vdYEbnO-o6amjpGx9G6mva2Sn4MrjRlWZH-8jYbhwuyFltdoNd_Ow5eb292azuk_XT3cPqep0UDIAniBlWIKzlvMozW_MiU4U1qlYMGZNxFmkplKyrUpUlYs1MzlIpJaRYI1ZiTi6PufHdt8kOo976KXSxUnMpuUIRa_6jWKaEEDwDjJQ4UkW71X1wrQl7zUAfDOtfw_pgWB8N62hYfAO9x3CZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1873332806</pqid></control><display><type>article</type><title>PS-070 Thromboprophylaxis optimisation in a cohort of neurocritical patients</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Rivera-Sanchez, L ; Lalueza-Broto, P ; Juarez-Gimenez, JC ; Girona-Brumos, L ; Robles-Gonzalez, A ; Baguena-Martinez, M</creator><creatorcontrib>Rivera-Sanchez, L ; Lalueza-Broto, P ; Juarez-Gimenez, JC ; Girona-Brumos, L ; Robles-Gonzalez, A ; Baguena-Martinez, M</creatorcontrib><description>BackgroundNeurocritical patients have a significant risk of developing further venous thromboembolisms. Therefore, appropriate use of pharmacological and mechanical thromboprophylaxis (TP) is needed to reduce the incidence of these events.PurposeThe aim of this study was to compare the use of TP in two cohorts of neurocritical patients, before and after implementation of corrective measures.Material and methodsA retrospective study of the use of TP was performed in two cohorts of neurocritical patients during their stay in the intensive care unit (ICU). The study was undertaken for the period of time from July to September 2013, and from July to September 2016. Demographic and TP related data were collected. Patients with anticoagulant therapy prior to hospital admission were not included.ResultsWe included 30 patients (86.6% men), mean age 45.5 years (16–80) in 2013, and 20 patients (75% men), mean age 48.7 years (17–83) in 2016. Median length of stay in the ICU was 17 days (3–51) in 2013 and 16 days (4–48) in 2016. The main diagnoses at admission in 2013 and 2016 were, respectively, acute spinal cord injury (30% vs 50%), stroke (26.6% vs 0%), head injury (23.3% vs 35%) and subarachnoid haemorrhage (3.3% vs 15%). 2013 2016 Mechanical prophylaxis alone (intermittent pneumatic compression, IPC) Treated patients3.8%15%MST1.71 (same day)MTD12.318.5 Pharmacological prophylaxis alone (LMWH) Treated patients48.1%20%MST5.43.25MTD8.710 Mixed prophylaxis (IPC+LMWH) Treated patients48.1%65%MST13.74.8MTD11.919.8MST, mean days before treatment; MTD, mean days of treatment.ConclusionAfter TP corrective measures were implemented, we observed the following improvements:100% of patients received some method of TP, exceeding the 90% recommended by the Spanish Intensive Society (quality indicator selected), and higher than in 2013 (90%).There was an improvement in TP startup time, both mechanical TP and pharmacological TP, as recommended by different clinical practice guidelines.An increase in the use of mechanical (51.9% vs 80%) and mixed prophylaxis (48% vs 65%) was documented.No conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2017-000640.576</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Disease prevention</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A257-A260</ispartof><rights>2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2017 (c) 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>2017 2017, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Rivera-Sanchez, L</creatorcontrib><creatorcontrib>Lalueza-Broto, P</creatorcontrib><creatorcontrib>Juarez-Gimenez, JC</creatorcontrib><creatorcontrib>Girona-Brumos, L</creatorcontrib><creatorcontrib>Robles-Gonzalez, A</creatorcontrib><creatorcontrib>Baguena-Martinez, M</creatorcontrib><title>PS-070 Thromboprophylaxis optimisation in a cohort of neurocritical patients</title><title>European journal of hospital pharmacy. Science and practice</title><description>BackgroundNeurocritical patients have a significant risk of developing further venous thromboembolisms. Therefore, appropriate use of pharmacological and mechanical thromboprophylaxis (TP) is needed to reduce the incidence of these events.PurposeThe aim of this study was to compare the use of TP in two cohorts of neurocritical patients, before and after implementation of corrective measures.Material and methodsA retrospective study of the use of TP was performed in two cohorts of neurocritical patients during their stay in the intensive care unit (ICU). The study was undertaken for the period of time from July to September 2013, and from July to September 2016. Demographic and TP related data were collected. Patients with anticoagulant therapy prior to hospital admission were not included.ResultsWe included 30 patients (86.6% men), mean age 45.5 years (16–80) in 2013, and 20 patients (75% men), mean age 48.7 years (17–83) in 2016. Median length of stay in the ICU was 17 days (3–51) in 2013 and 16 days (4–48) in 2016. The main diagnoses at admission in 2013 and 2016 were, respectively, acute spinal cord injury (30% vs 50%), stroke (26.6% vs 0%), head injury (23.3% vs 35%) and subarachnoid haemorrhage (3.3% vs 15%). 2013 2016 Mechanical prophylaxis alone (intermittent pneumatic compression, IPC) Treated patients3.8%15%MST1.71 (same day)MTD12.318.5 Pharmacological prophylaxis alone (LMWH) Treated patients48.1%20%MST5.43.25MTD8.710 Mixed prophylaxis (IPC+LMWH) Treated patients48.1%65%MST13.74.8MTD11.919.8MST, mean days before treatment; MTD, mean days of treatment.ConclusionAfter TP corrective measures were implemented, we observed the following improvements:100% of patients received some method of TP, exceeding the 90% recommended by the Spanish Intensive Society (quality indicator selected), and higher than in 2013 (90%).There was an improvement in TP startup time, both mechanical TP and pharmacological TP, as recommended by different clinical practice guidelines.An increase in the use of mechanical (51.9% vs 80%) and mixed prophylaxis (48% vs 65%) was documented.No conflict of interest</description><subject>Disease prevention</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE1LxDAQhoMouKz7HwKeu06SZtIeZfELFhVczyFtU5pl29S0BffmxT_qLzHLqkcvM3N4eN_hIYQyWDIm8Mpum74xoU04MJUAAKawlApPyIxDqpI8x_T075Z4ThbD4AqQQmR5KvIZeXx-SUDB18fnpgm-LXwffN_sd-bdDdT3o2vdYEbnO-o6amjpGx9G6mva2Sn4MrjRlWZH-8jYbhwuyFltdoNd_Ow5eb292azuk_XT3cPqep0UDIAniBlWIKzlvMozW_MiU4U1qlYMGZNxFmkplKyrUpUlYs1MzlIpJaRYI1ZiTi6PufHdt8kOo976KXSxUnMpuUIRa_6jWKaEEDwDjJQ4UkW71X1wrQl7zUAfDOtfw_pgWB8N62hYfAO9x3CZ</recordid><startdate>201703</startdate><enddate>201703</enddate><creator>Rivera-Sanchez, L</creator><creator>Lalueza-Broto, P</creator><creator>Juarez-Gimenez, JC</creator><creator>Girona-Brumos, L</creator><creator>Robles-Gonzalez, A</creator><creator>Baguena-Martinez, M</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>201703</creationdate><title>PS-070 Thromboprophylaxis optimisation in a cohort of neurocritical patients</title><author>Rivera-Sanchez, L ; Lalueza-Broto, P ; Juarez-Gimenez, JC ; Girona-Brumos, L ; Robles-Gonzalez, A ; Baguena-Martinez, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1002-6686d03ee22d98ef2b87bea7f716115716b4c375fdc7cc66f1a914555046f66d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Disease prevention</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rivera-Sanchez, L</creatorcontrib><creatorcontrib>Lalueza-Broto, P</creatorcontrib><creatorcontrib>Juarez-Gimenez, JC</creatorcontrib><creatorcontrib>Girona-Brumos, L</creatorcontrib><creatorcontrib>Robles-Gonzalez, A</creatorcontrib><creatorcontrib>Baguena-Martinez, M</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rivera-Sanchez, L</au><au>Lalueza-Broto, P</au><au>Juarez-Gimenez, JC</au><au>Girona-Brumos, L</au><au>Robles-Gonzalez, A</au><au>Baguena-Martinez, M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PS-070 Thromboprophylaxis optimisation in a cohort of neurocritical patients</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2017-03</date><risdate>2017</risdate><volume>24</volume><issue>Suppl 1</issue><spage>A257</spage><epage>A260</epage><pages>A257-A260</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>BackgroundNeurocritical patients have a significant risk of developing further venous thromboembolisms. Therefore, appropriate use of pharmacological and mechanical thromboprophylaxis (TP) is needed to reduce the incidence of these events.PurposeThe aim of this study was to compare the use of TP in two cohorts of neurocritical patients, before and after implementation of corrective measures.Material and methodsA retrospective study of the use of TP was performed in two cohorts of neurocritical patients during their stay in the intensive care unit (ICU). The study was undertaken for the period of time from July to September 2013, and from July to September 2016. Demographic and TP related data were collected. Patients with anticoagulant therapy prior to hospital admission were not included.ResultsWe included 30 patients (86.6% men), mean age 45.5 years (16–80) in 2013, and 20 patients (75% men), mean age 48.7 years (17–83) in 2016. Median length of stay in the ICU was 17 days (3–51) in 2013 and 16 days (4–48) in 2016. The main diagnoses at admission in 2013 and 2016 were, respectively, acute spinal cord injury (30% vs 50%), stroke (26.6% vs 0%), head injury (23.3% vs 35%) and subarachnoid haemorrhage (3.3% vs 15%). 2013 2016 Mechanical prophylaxis alone (intermittent pneumatic compression, IPC) Treated patients3.8%15%MST1.71 (same day)MTD12.318.5 Pharmacological prophylaxis alone (LMWH) Treated patients48.1%20%MST5.43.25MTD8.710 Mixed prophylaxis (IPC+LMWH) Treated patients48.1%65%MST13.74.8MTD11.919.8MST, mean days before treatment; MTD, mean days of treatment.ConclusionAfter TP corrective measures were implemented, we observed the following improvements:100% of patients received some method of TP, exceeding the 90% recommended by the Spanish Intensive Society (quality indicator selected), and higher than in 2013 (90%).There was an improvement in TP startup time, both mechanical TP and pharmacological TP, as recommended by different clinical practice guidelines.An increase in the use of mechanical (51.9% vs 80%) and mixed prophylaxis (48% vs 65%) was documented.No conflict of interest</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2017-000640.576</doi></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A257-A260
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2552763002
source EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Disease prevention
title PS-070 Thromboprophylaxis optimisation in a cohort of neurocritical patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A25%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PS-070%E2%80%85Thromboprophylaxis%20optimisation%20in%20a%20cohort%20of%20neurocritical%20patients&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Rivera-Sanchez,%20L&rft.date=2017-03&rft.volume=24&rft.issue=Suppl%201&rft.spage=A257&rft.epage=A260&rft.pages=A257-A260&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2017-000640.576&rft_dat=%3Cproquest_bmj_p%3E2552763002%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1873332806&rft_id=info:pmid/&rfr_iscdi=true